[1] Abdalla AF, Zalata KR, Ismail AF, et al. Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods. Fibrogenesis Tissue Repair,2009, 2: 2.
[2] Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology, 2001, 34: 659-665.
[3] Desmet VJ, Knodell RG, Ishak KG, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. J Hepatol, 2003, 38: 382-386.
[4] Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981, 1: 431-435.
[5] Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol, 1991, 13: 372-374.
[6] Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol, 1995, 22: 696-699.
[7] 刘霞, 王泰龄, 赵恭华,等. 慢性丙型肝炎病理分级分期特点及与乙型肝炎的比较研究. 中日友好医院学报, 2005: 133-136,194.
[8] De Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet, 1968, 2: 626-628.
[9] Salmi M, Adams D, Jalkanen S. Cell adhesion and migration. IV. Lymphocyte trafficking in the intestine and liver. Am J Physiol,1998, 274: G1-6.
[10] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 1996, 24: 289-293.
[11] Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology, 1993, 104: 595-603.
[12] Bedossa P, Poynard T. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology, 1994, 20: 15-20.
[13] Shiha G, Zalata K. Ishak versus METAVIR: terminology, convertibility and correlation with laboratory changes in chronic hepatitis C, liver biopsy, 2011,155-170.
[14] Maria Elzbieta SL, Marek LD. Histological outcome of chronic hepatitis B in children treated with interferon alpha. World J Gastroenterol, 2005, 11: 7179-7182.
[15] Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol, 2003, 38: 223-229.
[16] Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol, 2007, 47: 598-607.
[17] Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int, 2015, 35:78-81.
[18] Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med,2006, 354: 1001-1010.
[19] Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol, 2003, 39: 239-244.
[20] Wang Y, Vincent R, Yang J, et al. Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis. Hepatology, 2017, 65: 1891-1903.
[21] Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med, 2000, 124: 1599-1607.
[22] Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology, 2017, 65: 1438-1450.
[23] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepa-tology, 2016, 64: 73-84.
[24] Wong VW, Wong GL, Yeung JC, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology, 2016, 63: 754-763.
[25] Guido M, Sarcognato S, Sonzogni A, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int, 2016, 36: 454-460.
[26] Ohbu M, Okudaira M, Watanabe K, et al. Histopathological study of intrahepatic aberrant vessels in cases of noncirrhotic portal hypertension. Hepatology, 1994, 20: 302-308.
[27] Guido M, Sarcognato S, Russo FP, et al. Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. Liver Int, 2018,38:1770-1776. |
